Stay updated with breaking news from Anders Ullman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Annualised bleed rate (ABR), injection frequency and factor consumption were significantly lower compared to standard half-life (SHL) FVIII prophylaxis Results demonstrated the superior
Congress in London, demonstrating improved prophylactic effectiveness in Elocta® (efmoroctocog alfa) treated...
Annualised bleed rate among haemophilia A patients was significantly lower in real-world setting - News - PharmaTimes
Investigational once-weekly efanesoctocog alfa prophylaxis met the primary efficacy endpoint providing clinically meaningful bleed protection for people with severe hemophilia AResults underscore the ability of efanesoctocog alfa to sustain normal to near-normal factor levels and the potential to transform prophylac...
Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis Investigational once-weekly efanesoctocog alfa prophylaxis met the